ArticleNeurology(R) neuroimmunology & neuroinflammation2016

Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug.

Adil Javed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.